Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
An Agentic Framework for Rapid Deployment of Edge AI Solutions in Industry 5.0
arXiv:2510.25813v1 Announce Type: new Abstract: We present a novel framework for Industry 5.0 that simplifies the deployment of AI models on edge devices in various industrial settings. The design reduces latency and avoids external data transfer by enabling local inference and real-time processing. Our implementation is agent-based, which means that individual agents, whether human, algorithmic, or collaborative, are responsible for well-defined tasks, enabling flexibility and simplifying inte
-
cs.AI, q-bio.NC updates on arXiv.org
-
SciTrust 2.0: A Comprehensive Framework for Evaluating Trustworthiness of Large Language Models in Scientific Applications
arXiv:2510.25908v1 Announce Type: new Abstract: Large language models (LLMs) have demonstrated transformative potential in scientific research, yet their deployment in high-stakes contexts raises significant trustworthiness concerns. Here, we introduce SciTrust 2.0, a comprehensive framework for evaluating LLM trustworthiness in scientific applications across four dimensions: truthfulness, adversarial robustness, scientific safety, and scientific ethics. Our framework incorporates novel, open-e
SciTrust 2.0: A Comprehensive Framework for Evaluating Trustworthiness of Large Language Models in Scientific Applications
-
cs.AI, q-bio.NC updates on arXiv.org
-
Human-AI Complementarity: A Goal for Amplified Oversight
arXiv:2510.26518v1 Announce Type: new Abstract: Human feedback is critical for aligning AI systems to human values. As AI capabilities improve and AI is used to tackle more challenging tasks, verifying quality and safety becomes increasingly challenging. This paper explores how we can leverage AI to improve the quality of human oversight. We focus on an important safety problem that is already challenging for humans: fact-verification of AI outputs. We find that combining AI ratings and human r
Human-AI Complementarity: A Goal for Amplified Oversight
-
cs.AI, q-bio.NC updates on arXiv.org
-
Agentic AI Home Energy Management System: A Large Language Model Framework for Residential Load Scheduling
arXiv:2510.26603v1 Announce Type: new Abstract: The electricity sector transition requires substantial increases in residential demand response capacity, yet Home Energy Management Systems (HEMS) adoption remains limited by user interaction barriers requiring translation of everyday preferences into technical parameters. While large language models have been applied to energy systems as code generators and parameter extractors, no existing implementation deploys LLMs as autonomous coordinators
Agentic AI Home Energy Management System: A Large Language Model Framework for Residential Load Scheduling
-
cs.AI, q-bio.NC updates on arXiv.org
-
Identity Management for Agentic AI: The new frontier of authorization, authentication, and security for an AI agent world
arXiv:2510.25819v1 Announce Type: cross Abstract: The rapid rise of AI agents presents urgent challenges in authentication, authorization, and identity management. Current agent-centric protocols (like MCP) highlight the demand for clarified best practices in authentication and authorization. Looking ahead, ambitions for highly autonomous agents raise complex long-term questions regarding scalable access control, agent-centric identities, AI workload differentiation, and delegated authority. Th
Identity Management for Agentic AI: The new frontier of authorization, authentication, and security for an AI agent world
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-Agent Reinforcement Learning for Market Making: Competition without Collusion
arXiv:2510.25929v1 Announce Type: cross Abstract: Algorithmic collusion has emerged as a central question in AI: Will the interaction between different AI agents deployed in markets lead to collusion? More generally, understanding how emergent behavior, be it a cartel or market dominance from more advanced bots, affects the market overall is an important research question. We propose a hierarchical multi-agent reinforcement learning framework to study algorithmic collusion in market making. T
Multi-Agent Reinforcement Learning for Market Making: Competition without Collusion
-
cs.AI, q-bio.NC updates on arXiv.org
-
The Quest for Reliable Metrics of Responsible AI
arXiv:2510.26007v1 Announce Type: cross Abstract: The development of Artificial Intelligence (AI), including AI in Science (AIS), should be done following the principles of responsible AI. Progress in responsible AI is often quantified through evaluation metrics, yet there has been less work on assessing the robustness and reliability of the metrics themselves. We reflect on prior work that examines the robustness of fairness metrics for recommender systems as a type of AI application and summa
The Quest for Reliable Metrics of Responsible AI
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v2 Announce Type: replace-cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositio
Integrating Genomics into Multimodal EHR Foundation Models
-
Nature - Issue - nature.com science feeds
-
Multi-omic profiling reveals age-related immune dynamics in healthy adults
Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09686-5This multi-omic longitudinal analysis of the healthy human peripheral immune system constructs the Human Immune Health Atlas and assembles data on immune cell composition and state changes with age, including responses to cytomegalovirus infection and influenza vaccination.
Multi-omic profiling reveals age-related immune dynamics in healthy adults
Nature, Published online: 29 October 2025; doi:10.1038/s41586-025-09686-5
This multi-omic longitudinal analysis of the healthy human peripheral immune system constructs the Human Immune Health Atlas and assembles data on immune cell composition and state changes with age, including responses to cytomegalovirus infection and influenza vaccination.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics
Diagnostics (Basel). 2025 Oct 14;15(20):2586. doi: 10.3390/diagnostics15202586.ABSTRACTThe integration of multi-omics technologies is transforming the landscape of cancer management, offering unprecedented insights into tumor biology, early diagnosis, and personalized therapy. This review provides a comprehensive overview of the current state of omics approaches, with a particular focus on the application of genomics, NMR-based metabolomics, and radiomics in non-small cell lung cancer (NSCLC). G
Advancing Non-Small-Cell Lung Cancer Management Through Multi-Omics Integration: Insights from Genomics, Metabolomics, and Radiomics
Diagnostics (Basel). 2025 Oct 14;15(20):2586. doi: 10.3390/diagnostics15202586.
ABSTRACT
The integration of multi-omics technologies is transforming the landscape of cancer management, offering unprecedented insights into tumor biology, early diagnosis, and personalized therapy. This review provides a comprehensive overview of the current state of omics approaches, with a particular focus on the application of genomics, NMR-based metabolomics, and radiomics in non-small cell lung cancer (NSCLC). Genomics currently represents one of the most established omics technologies in oncology, as it enables the identification of genetic alterations that drive tumor initiation, progression, and therapeutic response. Interestingly, genomic analyses have revealed that many tumors harbor mutations in genes encoding metabolic enzymes, thus establishing a tight connection between genomics and tumor metabolism. In parallel, metabolomics profiling-by capturing the metabolic phenotype of tumors-has, in recent years, identified specific biomarkers associated with tumor burden, progression, and prognosis. Such findings have catalyzed growing interest in metabolomics as a complementary approach to better characterize cancer biology and discover novel diagnostic and therapeutic targets. Moreover, radiomics, through the extraction of quantitative features from standard imaging modalities, captures tumor heterogeneity and contributes predictive information on tumor biology, treatment response, and clinical outcomes. As a non-invasive and widely available technique, radiomics has the potential to support longitudinal monitoring and individualized treatment planning. Both metabolomics and radiomics, when integrated with genomic data, could support a more comprehensive understanding of NSCLC and pave the way for the development of non-invasive, predictive models and personalized therapeutic strategies. In addition, we explore the specific contributions of these technologies in enhancing clinical decision-making for lung cancer patients, with particular attention to their potential in early diagnosis, treatment selection, and real-time monitoring.
PMID:41153258 | DOI:10.3390/diagnostics15202586
-
cs.AI, q-bio.NC updates on arXiv.org
-
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor genera
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v1 Announce Type: cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositions. The
Integrating Genomics into Multimodal EHR Foundation Models
-
cs.AI, q-bio.NC updates on arXiv.org
-
Closing Gaps: An Imputation Analysis of ICU Vital Signs
arXiv:2510.24217v1 Announce Type: cross Abstract: As more Intensive Care Unit (ICU) data becomes available, the interest in developing clinical prediction models to improve healthcare protocols increases. However, the lack of data quality still hinders clinical prediction using Machine Learning (ML). Many vital sign measurements, such as heart rate, contain sizeable missing segments, leaving gaps in the data that could negatively impact prediction performance. Previous works have introduced num
Closing Gaps: An Imputation Analysis of ICU Vital Signs
-
Omics in Gastric
-
The Role of Omentin in Gastrointestinal Cancer: Diagnostic, Prognostic, and Therapeutic Perspectives
Metabolites. 2025 Sep 30;15(10):649. doi: 10.3390/metabo15100649.ABSTRACTBackground/Objectives: Omentin, also known as intelectin-1, is a secreted adipokine with anti-inflammatory, insulin-sensitizing, and immune-modulatory functions, primarily expressed in visceral adipose tissue. While omentin has been associated with favorable metabolic outcomes, its role in cancer pathogenesis appears context-dependent and remains poorly understood. This review investigates the biological functions, expressi
The Role of Omentin in Gastrointestinal Cancer: Diagnostic, Prognostic, and Therapeutic Perspectives
Metabolites. 2025 Sep 30;15(10):649. doi: 10.3390/metabo15100649.
ABSTRACT
Background/Objectives: Omentin, also known as intelectin-1, is a secreted adipokine with anti-inflammatory, insulin-sensitizing, and immune-modulatory functions, primarily expressed in visceral adipose tissue. While omentin has been associated with favorable metabolic outcomes, its role in cancer pathogenesis appears context-dependent and remains poorly understood. This review investigates the biological functions, expression patterns, and clinical relevance of omentin across gastrointestinal malignancies. Methods: A comprehensive review of the literature was conducted using PubMed, Scopus, and Web of Science up to August 2025 to evaluate the role of omentin in gastrointestinal cancers. Both preclinical and clinical studies evaluating omentin, its analogues and omentin-enhancing agents in gastric, colorectal, hepatic, pancreatic, and esophageal cancers were included. Results: Omentin exhibits anti-proliferative, anti-inflammatory, and anti-angiogenic effects within the tumor microenvironment in several GI malignancies. However, evidence also indicates a dual role. High intratumoral omentin expression correlates with improved prognosis in colorectal, gastric, and hepatic cancers; in contrast, elevated circulating levels-particularly in colorectal and pancreatic cancers-have been paradoxically associated with increased cancer risk and poor outcomes. Mechanistically, omentin modulates PI3K/Akt, NF-κB, AMPK, and oxidative stress pathways, and interacts with TMEM207. However, most available studies are small-scale and heterogeneous, with methodological inconsistencies and limited multi-omics integration, leaving major knowledge gaps. Conclusions: This review highlights omentin's distinct systemic and local roles across GI cancers, underscoring its translational implications. Omentin emerges as a promising but context-dependent biomarker and therapeutic target, with future research needed to address heterogeneity, standardize assays, and validate its clinical utility in large-scale prospective studies.
PMID:41149627 | PMC:PMC12566161 | DOI:10.3390/metabo15100649
-
(Multiomics OR Omics) AND (Pancreatic)
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
Understanding AI Trustworthiness: A Scoping Review of AIES & FAccT Articles
arXiv:2510.21293v2 Announce Type: replace Abstract: Background: Trustworthy AI serves as a foundational pillar for two major AI ethics conferences: AIES and FAccT. However, current research often adopts techno-centric approaches, focusing primarily on technical attributes such as reliability, robustness, and fairness, while overlooking the sociotechnical dimensions critical to understanding AI trustworthiness in real-world contexts. Objectives: This scoping review aims to examine how the AIES
Understanding AI Trustworthiness: A Scoping Review of AIES & FAccT Articles
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
Benchmarking AI Models in Software Engineering: A Review, Search Tool, and Unified Approach for Elevating Benchmark Quality
arXiv:2503.05860v2 Announce Type: replace-cross Abstract: Benchmarks are essential for unified evaluation and reproducibility. The rapid rise of Artificial Intelligence for Software Engineering (AI4SE) has produced numerous benchmarks for tasks such as code generation and bug repair. However, this proliferation has led to major challenges: (1) fragmented knowledge across tasks, (2) difficulty in selecting contextually relevant benchmarks, (3) lack of standardization in benchmark creation, and (
Benchmarking AI Models in Software Engineering: A Review, Search Tool, and Unified Approach for Elevating Benchmark Quality
-
Omics In Lung
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
ProfileXAI: User-Adaptive Explainable AI
arXiv:2510.22998v1 Announce Type: new Abstract: ProfileXAI is a model- and domain-agnostic framework that couples post-hoc explainers (SHAP, LIME, Anchor) with retrieval - augmented LLMs to produce explanations for different types of users. The system indexes a multimodal knowledge base, selects an explainer per instance via quantitative criteria, and generates grounded narratives with chat-enabled prompting. On Heart Disease and Thyroid Cancer datasets, we evaluate fidelity, robustness, parsim